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Background/aim: Sepsis is still a major cause of morbidity and mortality despite the improvements in diagnosis and treatment. The aim
of this study was to investigate the values of procalcitonin and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in
the differential diagnosis of patients with sepsis and noninfectious systemic inflammatory response syndrome (NI-SIRS) and measure
their importance in the prognosis of patients with sepsis.
Materials and methods: This prospective study included 41 NI-SIRS and 33 sepsis patients hospitalized in Celal Bayar University
Hospital, Manisa, Turkey. Blood samples were taken from NI-SIRS patients on days 0 and 3 and from sepsis patients on days 0, 3, 4, 7,
and 14. Clinical status of the patients was determined with the SOFA scoring system.
Results: The SOFA scoring system and procalcitonin and sTREM-1 measurements were significant in the differential diagnosis of
sepsis and NI-SIRS patients. The SOFA scoring system was considered the most important indicator in determining the prognosis of
sepsis patients. Procalcitonin and sTREM-1 levels increased progressively in nonsurvivors and decreased in survivors, but changes were
statistically insignificant.
Conclusion: In the differentiation of sepsis and NI-SIRS, and evaluation of the prognosis of sepsis, combined measurements of
procalcitonin and sTREM-1 levels are important.
Key words: Procalcitonin, sepsis, SIRS, SOFA, sTREM-1

1. Introduction
Sepsis is a fatal infectious disease that involves multiple
organ systems, leads to hemodynamic changes, and causes
shocks, organ dysfunction, and organ failure. It is ranked
as the thirteenth leading cause of death in the US and the
second leading cause of death in intensive care units (ICUs)
other than coronary ICUs. In recent years, due to the
increases in aggressive therapies and invasive procedures,
sepsis incidence and sepsis-associated mortality rates have
increased (1,2).
Nonspecific clinical signs in the initial period of sepsis
may lead to unnecessary or delayed use of antibiotics.
Therefore, laboratory investigations yielding rapid and
accurate results to support the diagnosis are needed.
Blood culture growth, the differential diagnosis criterion,

cannot be achieved in all patients, and the results cannot
be obtained earlier than 24 h. On the other hand, when
attempting to confirm the absence of infection in patients
suspected to have sepsis but in fact not having sepsis,
serious diagnostic problems arise (3).
In recent years, studies conducted on the early diagnosis
of sepsis have focused not only on the rapid diagnosis of
the causative microorganisms but also on some indicators
of host inflammatory response triggered by these
microorganisms. However, to date, to achieve early, quick,
and accurate diagnosis of sepsis, no single laboratory
test with high sensitivity and specificity has been found.
For this purpose, the efficacy of several immunological,
hematological, and biochemical diagnostic indicators
alone or in combination has been investigated (4,5).

* This work was presented at the 21st ECCMID/27th ICC, 07–11 May 2011, Milan, Italy.
** Correspondence: otunger@hotmail.com
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Procalcitonin, the precursor molecule of the calcitonin
hormone, was defined in neonatal sepsis for the first time
and has been one of the most-studied molecules in the
early diagnosis of sepsis (6). It is a useful marker used
in the determination of the severity of the infection, the
prediction of prognosis, and monitoring the response to
the treatment (5,7).
In addition to procalcitonin, triggering receptor
expressed on myeloid cells-1 (TREM-1) has been another
studied molecule in recent years. TREM-1 is a member
of the immunoglobulin superfamily released from
phagocytic cells in the presence of bacterial and fungal
infections. Soluble TREM-1 (sTREM-1) is released from
activated phagocytes and can be detected in body fluids
(8). Therefore, it is important to investigate sTREM-1
plasma levels for the diagnosis of patients with severe
infection and to differentiate the infectious inflammatory
response from the noninfectious inflammatory response
(8,9). In several studies, a correlation between sTREM-1
and procalcitonin, both of which are important markers in
the prognosis of patients with sepsis, has been determined
(5,10,11).
This study aimed to investigate the role of procalcitonin
and sTREM-1 in differentiating patients with sepsis
from patients with noninfectious systemic inflammatory
response syndrome (NI-SIRS) and to determine
procalcitonin and sTREM-1 values in the prognosis of
patients with sepsis.
2. Materials and methods
The study was designed as a prospective study including
74 patients (41 with NI-SIRS and 33 with sepsis) who were
hospitalized and treated in Celal Bayar University (CBU)
Hospital.
Of the NI-SIRS and sepsis patients, those who met
at least two of the SIRS criteria (core temperature >38
°C or <36 °C; heart rate >90 beats/min; respiratory rate
>20 breaths/min or arterial partial pressure of carbon
dioxide <32 mmHg or requirement for mechanical
ventilation for an acute pathological process; white blood
cell count >12,000 /mm3 or <4000 /mm3 or more than
10% immature neutrophils) were included in the study
(12). In addition, in order not to not cause any diagnostic
confusion, only sepsis patients with microbiological
evidence were included in the sepsis group. Those with
immunodeficiency and/or malignancy, having undergone
organ transplantation, taking corticosteroids more than 1
mg/kg per day, younger than 18 years old, or older than 80
years old were not included in the study.
The patients in the study group were visited at regular
intervals and assessed clinically, and the demographic data
and clinical and laboratory findings related to them were
recorded on a follow-up form prepared in advance. For the

clinical follow-up of the patients, the sepsis-related organ
failure assessment (SOFA) scoring system was used (12,13).
In order to determine the role of procalcitonin and
sTREM-1 markers in differentiating sepsis and NI-SIRS
cases from each other, blood samples were taken from the
patients in both groups on days 0 and 3. The role of these
immunological markers in the prognosis of patients with
sepsis was investigated by taking blood samples from the
sepsis patients on days 4, 7, 14, and 21, in addition to days 0
and 3. After the sera were separated, all the blood samples
taken from the patients were stored at –80 °C. While
plasma procalcitonin concentrations were investigated
with the enzyme-linked fluorescent assay method (VIDAS
BRAHMS PCT, France), sTREM-1 levels were investigated
with the enzyme-linked immunosorbent assay method
(R & D Systems Human TREM-1 ELISA, USA) in the
biochemistry laboratory of CBU.
Blood samples and other clinical samples taken to
determine the focus of infection were examined in the
bacteriology laboratory of CBU. Standard microbiological
methods for the identification of the isolated
microorganisms and the determination of antimicrobial
susceptibility of these microorganisms were used (14).
The statistical analysis of the study was performed
with the SPSS for Windows 11.0. To assess the role of
procalcitonin and sTREM-1 in the differential diagnosis
of sepsis and NI-SIRS, Student’s t-test, the Mann–Whitney
U-test, and ROC analysis were used. The Mann–Whitney
U-test and ROC analysis were also used for the assessment
of prognostic values of SOFA, sTREM-1, and procalcitonin
in the patients with sepsis, and repeated measures analysis
of variance was used to determine the changes in each
variable during follow-up.
3. Results
While the demographic and clinical data of the patients
are given in Table 1, causes of sepsis and NI-SIRS are
summarized in Table 2. Statistically significant differences
were determined between the sepsis and NI-SIRS
patients in terms of age, being inpatient or outpatient,
ICU admission, antibiotic usage history, and underlying
diseases (liver failure, kidney failure, diabetes, chronic lung
disease, cardiovascular disease) (P < 0.05) (Table 1). Of the
microorganisms that cause sepsis, gram-negative bacteria
were determined to take the lead (60.6%) (Table 3).
In this study, the overall mortality rate was 54.54% in
the sepsis group (n = 18 patients) and of them, 16 (88.9%)
were followed in the ICU and 2 (11.1%) in the surgical
wards. On the other hand, the mortality rate in the SIRS
group was 21.9% (n = 9 patients).
When the SOFA scores and procalcitonin and
sTREM-1 markers were assessed to differentiate sepsis
cases from NI-SIRS cases, they were significantly higher
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Table 1. Demographic and clinical data of the patients.
Sepsis
n (%)

NI-SIRS
n (%)

P-value

Age (Mean ± SD)

58.1 ± 18.1

44 ± 17.53

0.001*

Sex
Male
Female
Total

17 (51.5)
16 (48.5)
33 (100.0)

27 (65.9)
14 (34.1)
41 (100.0)

Being inpatient or outpatient
Outpatient
Inpatient
Total

16 (48.5)
17 (51.5)
33 (100.0)

38 (92.7)
3 (7.3)
41(100.0)

Operation
Yes
No
Total

9 (27.3)
24 (72.7)
33 (100.0)

9 (22.0)
32 (78.0)
41(100.0)

Other Interventions#
Yes
No
Total

0 ( 0.0)
33 (100.0)
33 (100.0)

4 (9.8)
37 (90.2)
41(100.0)

Department
Intensive care
Internal medicine
Surgery
Total

23 (69.7)
7 (21.2)
3 (9.1)
33 (100.0)

16 (39.0)
13 (31.7)
12 (29.3)
41(100.0)

Antibiotic usage history
Yes
No
Total

12 (36.4)
21 (63.6)
33 (100.0)

2 (4.9)
39 (95.1)
41(100.0)

0.001**

Underlying disease
Hepatic failure
Renal failure
Neurologic disorder
Diabetes mellitus
COPDχ
CVDƒ

5 (15.2)
12 (36.4)
13 (39.4)
10 (30.3)
5 (15.2)
8 (24.2)

0 (0.0)
3 (7.3)
8 (19.5)
4 (9.8)
0 (0.0)
2 (4.8)

0.015***
0.002**
0.059**
0.025**
0.015**
0.020**

0.2**

0.001**

0.5**

0.1**

0.02**

* Student’s t test.
** χ2 test.
*** Fisher’s exact χ2 test.
#
Other interventions: endoscopy, endoscopic retrograde cholangiopancreatography, thoracentesis, paracentesis,
stent placement, angiography.
χ
COPD: Chronic obstructive pulmonary disease.
ƒ
CVD: Cardiovascular disease.

in the patients with sepsis than were those in the NI-SIRS
patients on days 0 and 3 (P = 0.001, Mann–Whitney U-test
and Student’s t-test) (Table 4).
In order to determine the role of all the three
parameters in the differentiation of sepsis from NI-SIRS,
ROC analysis was performed. The results of ROC analysis
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were presented as area under the curve (AUC), P-values,
cut-off values, sensitivity, specificity, positive predictive
values, and negative predictive values (Table 5). We
found that the AUC, sensitivity, and specificity values of
SOFA, procalcitonin, and sTREM-1 were quite high for
differential diagnosis of sepsis and NI-SIRS.
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Table 2. Clinical diagnosis of NI-SIRS and sepsis cases.
NI-SIRS cases

n (%)

Polytrauma
Neurological disease
Gastroenterological disease
Burns
Malignant disease
Heatstroke
Respiratory disease

16 (39.02)
8 (19.51)
6 (14.63)
3 (7.31)
3 (7.31)
3 (7.31)
2 (4.87)

Clinical diagnosis

Ischemic stroke (5), intracerebral hemorrhage (3)
Gastrointestinal bleeding (2), pancreatitis (3), subileus (1)
Pulmonary embolism (1), pulmonary edema (1)

Sepsis cases
13 (39.39)
8 (24.24)
7 (21.21)
3 (9.09)
2 (6.06)

Respiratory tract
Gastrointestinal tract
Urinary tract
Skin/soft tissue
Central nervous system

Pneumonia (13)
Seconder peritonitis ( 6), intraabdominal abscess (2)
Pyelonephritis (7)
Diabetic foot (2), cellulitis (1)
Meningitis (2)

Table 3. Distribution of microorganisms isolated in the clinical samples of sepsis patients.
Microorganisms (n)

n (%)

Gram-negative

Escherichia coli (11)
Acinetobacter spp.(6)
Pseudomonas aeruginosa (1)
Klebsiella spp. (2)

20 (60.6)

Gram-positive

Staphylococcus aureus (2)
Coagulase negative staphylococcus (2)
Enterococcus spp. (2)
Streptococcus pneumoniae (1)

7 (21.2)

Other

Polymicrobial

6 (18.2)

Table 4. The SOFA scores and procalcitonin and sTREM-1 markers of the sepsis and NI-SIRS cases.
Sepsis

NI-SIRS

Median (min–max)

Mean ± SD

Median (min–max)

Mean ± SD

SOFA (day 0)

6 (0–16)

7.12 ± 3.95

1 (0–9)

1.73 ± 2.23

SOFA (day 3)

7 (0–16)

7.67 ± 4.67

0 (0–10)

1.07 ± 2.33

PCT# (day 0)

7.31 (0.16–201)

34.37 ± 51.79

0.41 (0.05–18.93)

2.65 ± 4.94

PCT# (day 3)

10.55 (0.28–201)

37.13 ± 55.42

0.21 (0.4–17.39)

1.20 ± 2.92

sTREM-1ƒ (day 0)

268.41 (43.5–137.7)

398.96 ± 308.37

154.43 (9.91–519.8)

162.12 ± 86.36

sTREM- 1ƒ (day 3)

307.23 (53.68–1442.88)

417.60 ± 332.17

118.81 (3.88–221.6)

118.61 ± 52.30

P-value
0.001*
0.001*
0.001**
0.001**
0.001**
0.001**

(ng/mL)
(pg/mL)
* Mann–Whitney U-test.
**Student’s t-test.
#
ƒ
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Table 5. The predictive value of procalcitonin and sTREM-1 for differential diagnosis of sepsis and SIRS.
Cut-off value

AUC*

P

Sensitivity (%)

Specificity (%)

PPVχ

NPVδ

SOFA (day 0)

3.5

0.891

0.001

81.8

80.5

77.1

84.6

SOFA (day 3)

1.5

0.907

0.001

90.3

85.4

82.4

92.1

PCT# (day 0)

1.63

0.837

0.001

81.8

70.7

69.2

82.9

PCT# (day 3)

1.26

0.894

0.001

80.6

80.0

75.8

84.2

sTREM-1 (day 0)

199.72

0.826

0.001

81.8

73.2

71.1

83.3

sTREM-1 (day 3)

159. 52

0.883

0.001

80.6

80.5

75.8

84.6

ƒ
ƒ

AUC: Area under the curve.
PPV: Positive predictive value.
δ
NPV: Negative predictive value.
#
(ng/mL)
ƒ
(pg/mL)
*

χ

In order to determine the prognostic values of SOFA
scores, procalcitonin, and sTREM-1 levels in patients with
sepsis, the values for survivors and nonsurvivors during
the follow-up on days 0, 3, 4, 7, and 14 were compared.
A decrease in the survivors and an increase in the

nonsurvivors were determined. Significant differences
were observed between the SOFA scores on all the days,
between the procalcitonin values only on days 7 and 14,
and between the sTREM-1 values on days 4, 7, and 14 (P <
0.05, Mann–Whitney U-test) (Table 6).

Table 6. The values of the SOFA scores and procalcitonin and sTREM-1 values for survivors and
nonsurvivors.
Survivors

Nonsurvivors

P*

SOFA score
(Mean ± SD)
day 0
day 3
day 4
day 7
day 14

4.33 ± 2.15
4.30 ± 2.95
3.69 ± 2.59
2.83 ± 2.44
2.20 ± 2.30
2.66 ± 1.15

9.44 ± 3.60
10.10 ± 4.17
12.00 ± 3.38
11.80 ± 3.08
12.75 ± 2.70
-

<0.05
<0.05
<0.05
<0.05
<0.05

PCT
(Mean ± SD) ng/mL
day 0
day 3
day 4
day 7
day 14

31.69 ± 46.40
29.11 ± 51.10
19.96 ± 37.30
3.76 ± 5.92
1.63 ± 3.08
1.08 ± 0.35

36.61 ± 57.1
42.92 ± 59.1
45.38 ± 57.7
39.91 ± 55.4
40.58 ± 57.8
-

>0.05
>0.05
>0.05
<0.05
<0.05

sTREM-1
(Mean ± SD) pg/mL
day 0
day 3
day 4
day 7
day 14

386.67 ± 244.20
320.02 ± 221.81
278.28 ± 172.08
216.43 ± 146.80
208.52 ± 163.16
85.54 ± 54.84

409.20 ± 360.06
488.08 ± 383.98
655.75 ± 684.65
600.30 ± 414.49
552.36 ± 214.37
-

>0.05
>0.05
<0.05
<0.05
<0.05

*Mann–Whitney U-test.
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4. Discussion
Sepsis is SIRS developing due to infection. Using only SIRS
criteria, it is difficult to differentiate sepsis cases from NISIRS patients. In addition to the SIRS criteria, laboratory
findings play a very important role in the early differential
diagnosis of these patients (1,12). Studies conducted on the
differential diagnosis of sepsis and NI-SIRS in recent years
have focused on the indicators which yield results more
rapidly in the early period. Among them, clinical scoring
systems such as the SOFA and immunological markers
such as procalcitonin and sTREM-1 are the leading ones
(3,7,13).
In their clinical study, Endo et al. (15) observed higher
procalcitonin levels in patients with sepsis, which they
considered important in differentiating severe sepsis
from NI-SIRS. The results obtained were consistent with
the SOFA scores. In a metaanalysis, in which 30 studies
involving 3244 patients were evaluated, procalcitonin

ROC analysis was also performed to determine the
prognostic value of these parameters. AUC, P-values,
sensitivity, specificity, positive predictive values, and
negative predictive values are presented in Table 7. It was
found that procalcitonin and sTREM-1 values were not as
significant as SOFA values in the estimation of prognosis
of sepsis cases in the early stage. Of these two indicators,
the procalcitonin value became significant from day 7
onwards and the sTREM-1 value became significant from
day 4 onwards.
Repeated measures analysis of variance was performed
to determine the changes in SOFA, procalcitonin, and
sTREM-1 values during follow-up. According to the results
of this analysis, the values for each variable were higher in
the nonsurvivors than in the survivors; however, the only
statistically significant difference was determined for the
SOFA values (P < 0.001, repeated measures multivariate
variance analysis) (Figures 1–3; Table 8).

Table 7. The prognostic values of SOFA, sTREM-1, and procalcitoninin the patients with sepsis.
Cut-off value

AUC*

P

Sensitivity (%)

Specificity (%)

PPVχ

NPVδ

day 0#

7.5

0.885

0.001

77.8

100.0

100.0

78.9

day 3

#

7.5

0.865

0.001

77.8

92.3

93.3

75.0

day 4

#

8.5

0.981

0.001

91.7

100.0

100.0

92.9

day 7#

7.5

1.000

0.001

100.0

100.0

100.0

100.0

day 14#

8.5

1.000

0.005

100.0

100.0

100.0

100.0

day 0#

6.56

0.520

0.842

50.0

46.7

52.9

43.8

day 3#

10.80

0.577

0.471

61.1

69.2

73.3

56.3

day 4#

14.78

0.686

0.115

75.0

76.9

75.0

76.9

4.46

0.833

0.008

80.0

75.0

72.7

81.8

1.44

0.950

0.011

100.0

80.0

66.7

100.0

SOFA score

PCT (ng/mL)

day 7

#

day 14

#

sTREM-1 (pg/mL)
day 0#

254.67

0.444

0.588

50.0

40.0

50.0

40.0

day 3

#

310.72

0.658

0.139

66.7

76.9

80.0

62.5

day 4

#

292.33

0.763

0.026

66.7

69.2

66.7

69.2

day 7#

307.09

0.896

0.002

80.0

83.3

80.0

83.3

day 14#

375.27

0.925

0.016

100.0

90.0

80.0

100.0

P < 0.05
AUC: Area under the curve.
χ
PPV: Positive predictive value.
δ
NPV: Negative predictive value.
#
*
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PCT

SOFA

60.00

Nonsurvivor

12.50

Nonsurvivor

50.00

10.00

40.00

7.50

30.00
20.00

5.00

.00

Survivor

2.50
0

3

4

7

DAY

14

Survivor

0.00
0

3

4

7

14

DAY

Figure 2. Repeated measures multivariate variance analysis for
procalcitonin.

Figure 1. Repeated measures multivariate variance analysis for
SOFA scores.
sTREM - 1
700.0
600.0

Nonsurvivor

500.0
400.0
300.0

Survivor

200.0
0

3

4

7

14

DAY

Figure 3. Repeated measures multivariate variance analysis for
sTREM-1.
Table 8. The results of repeated measures multivariate variance analysis of SOFA, procalcitonin,
and sTREM-1.
SOFA

PCT

sTREM-1

Group (nonsurvivor/survivor)

P = 0.001

P = 0.7

P = 0.7

Time (days 0, 3, 4, 7, 14)

P = 0.2

P = 0.3

P = 0.1

Group × time

P = 0.07

P = 0.2

P = 0.1

sensitivity in differentiating NI-SIRS patients from sepsis
patients was 77%, while the specificity was 79%. It was
emphasized that procalcitonin was useful in the early
diagnosis of sepsis both in surgical and in medical patients
(16). In Gibot et al.’s study conducted to investigate the
diagnostic values of both procalcitonin and sTREM-1,
laboratory findings of both markers were higher in
patients with sepsis (10). In another study investigating the
diagnostic value of the sTREM-1 in patients with sepsis
and NI-SIRS, sTREM-1 levels were significantly higher in
patients with sepsis than in patients with NI-SIRS (17). In a
metaanalysis of 13 studies, it was concluded that sTREM-1
levels could be considered a reliable biological marker
in bacterial infections (18). In another metaanalysis,
11 studies involving 1795 patients were evaluated, and
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sTREM-1’s sensitivity and specificity in differentiating NISIRS patients from sepsis patients were determined to be
79% and 80%, respectively (9). In our study too, both the
SOFA scores and the procalcitonin and sTREM-1 levels
were found to be significantly higher in the patients with
sepsis than in the NI-SIRS patients. In the differentiation
of NI-SIRS from sepsis, the sensitivity and specificity of
SOFA were 81.8% and 80.5%, respectively, the sensitivity
and specificity of procalcitonin were 81.8% and 70.7%,
respectively, and the sensitivity and specificity of sTREM-1
were 81.8% and 73.2%, respectively. These results were
consistent with those in the literature.
Despite the developments in the early diagnosis and
treatment of sepsis, it still leads to high mortality. In several
clinical trials conducted on mortality resulting from sepsis
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in different patient groups, the mortality rate ranged
between 22% and 50% (1,5,19). In our study, the mortality
rate in the sepsis group was 54.54%. Determination of the
prognosis of the disease in sepsis patients is as important
as its early diagnosis. However, it is difficult to predict
mortality, or in other words, to determine the prognosis.
As in studies on the differential diagnosis of sepsis and NISIRS, in studies conducted to determine the prognosis of
sepsis, the focus is on clinical scoring systems such as the
SOFA and immunological markers such as procalcitonin
and sTREM-1 (7,20,21).
Kenzaka et al. (20) indicated that mean SOFA scores
in patients with sepsis, severe sepsis, and septic shock
were directly proportionate to the severity of the disease.
Innocenti et al. (22) investigated the importance of various
clinical scores and biological parameters in the prognosis
of patients who presented to the emergency room with
sepsis and septic shock. The SOFA score had the best
mortality prediction ability (AOC 0.80, 95% confidence
interval 0.70–0.91) compared with other clinical scores
and biologic parameters. In our study too, similar results
were obtained for the SOFA scores. During the entire
follow-up of patients with sepsis, sensitivity and specificity
values of SOFA scores were highand the prognostic value
of the SOFA score was statistically significant.
Several studies conducted on the same topic report that
both procalcitonin and sTREM-1 are reliable indicators
in determining prognosis. Studies conducted in various
centers determined that procalcitonin and sTREM-1
levels were higher in nonsurviving sepsis patients than in
surviving sepsis patients (7,15,21,23). In another study,
it was emphasized that sTREM-1 had a prognostic value
particularly in the long-term follow-up (24). In our study
too, although the difference was not statistically significant,
procalcitonin and sTREM-1 values obtained during followup decreased in the survivors but gradually increased in
the nonsurvivors. The statistical insignificance might be
due to the fact that the number of people in the groups

decreased as the follow-up period lengthened. When the
data obtained in this study were evaluated in the light of
the data in the literature, not only the SOFA scores but
also procalcitonin and sTREM-1 values were important
indicators in determining the prognosis of patients with
sepsis.
In the literature, different sensitivity and specificity
results have been reported regarding the prognostic value
of procalcitonin and sTREM-1 (5,7,11,15,21,23). However,
there is no clinical study indicating that they are the
single biological indicator with sufficient sensitivity and
specificity. In general, clinical studies have been conducted
on the use of these biological indicators in combination
with each other or with clinical indicators such as SOFA
scores. In this present clinical study, the prognostic values
of procalcitonin and sTREM-1 were not as significant as
those of SOFA during the early stage of sepsis. Since the
sensitivity and specificity of procalcitonin and sTREM-1
increase markedly in later stages, these immunological
indicators can be used along with the SOFA in this stage.
Many risk factors related to interventions performed
for diagnosis and treatment, the host, and microorganisms
play a role in the development of sepsis. Of the factors
related to the host, age and underlying disease are the
most important risk factors (1,2,5,25). The findings of our
study regarding demographic data and risk factors were
consistent with those in the literature we reviewed. Age,
being inpatient or outpatient, ICU admission, antibiotic
usage history, and underlying diseases (liver failure, kidney
failure, diabetes, chronic lung disease, and cardiovascular
disease) were identified as the most significant risk factors.
In line with the data obtained, in order to make an
early diagnosis and to determine the prognosis of patients
suspected to have sepsis, monitoring procalcitonin and
sTREM-1 values would be useful. However, further clinical
studies are needed in order to determine the diagnostic
and prognostic values of these markers in sepsis.
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